Literature DB >> 19208898

Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.

Yusuke Moritoh1, Koji Takeuchi, Masatoshi Hazama.   

Abstract

Administration of an alpha-glucosidase inhibitor, voglibose, increases the secretion of glucagon-like peptide (GLP)-1, a key modulator of pancreatic islet hormone secretion and glucose homeostasis. In the present study, novel mechanisms by which voglibose increases active GLP-1 circulation were evaluated. Voglibose (0.001 and 0.005%) was administered in the diet to ob/ob mice for 1 day or 3 to 4 weeks to determine effects on incretin profiles and plasma activity of dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for GLP-1 degradation. Voglibose showed no direct inhibitory effect against DPP-4 in vitro (DPP-4 inhibitor alogliptin, IC(50) < 10 nM). Likewise, 1-day treatment with voglibose did not change plasma DPP-4 activity; however, it increased plasma active GLP-1 by 1.6- to 3.4-fold. After chronic treatment, voglibose stimulated GLP-1 secretion, as evidenced by the 1.3- to 1.5-fold increase in plasma active plus inactive amidated GLP-1 levels. Plasma DPP-4 activity was decreased unexpectedly by 40 to 51%, resulting from reduced plasma DPP-4 concentrations in voglibose-treated mice. Voglibose increased GLP-1 content by 1.5- to 1.6-fold and 1.4- to 1.6-fold in the lower intestine and colon, respectively. The increased GLP-1 content in the colon was associated with elevated expression of gut glucagon gene. Chronic treatment with voglibose resulted in 1.9- to 4.1-fold increase in active GLP-1 circulation, which was higher than 1-day treatment. A similar treatment with pioglitazone (0.03%), an insulin sensitizer, did not affect plasma DPP-4 activity or GLP-1 levels. These results suggest that increased GLP-1 secretion, decreased DPP-4 activity, and increased gut GLP-1 content may have contributed to increased active GLP-1 circulation after chronic treatment with voglibose in a glucose control-independent manner in ob/ob mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208898     DOI: 10.1124/jpet.108.148056

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Food protein-derived bioactive peptides in management of type 2 diabetes.

Authors:  Prasad Patil; Surajit Mandal; Sudhir Kumar Tomar; Santosh Anand
Journal:  Eur J Nutr       Date:  2015-07-08       Impact factor: 5.614

Review 2.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.

Authors:  Masamitsu Iwasa; Yoshihisa Yamada; Hiroyuki Kobayashi; Shinji Yasuda; Itta Kawamura; Shohei Sumi; Takeru Shiraki; Takahiko Yamaki; Hiroaki Ushikoshi; Arihiro Hattori; Takuma Aoyama; Kazuhiko Nishigaki; Genzou Takemura; Hisayoshi Fujiwara; Shinya Minatoguchi
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

4.  Effective therapy using voglibose for nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other treatment possibilities.

Authors:  Kazuki Nagai; Katsuhiko Matsumaru; Yutaka Takahashi; Noriko Nakamura
Journal:  Case Rep Gastroenterol       Date:  2011-06-10

5.  Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.

Authors:  Eric P Davidson; Lawrence J Coppey; Brian Dake; Mark A Yorek
Journal:  Exp Diabetes Res       Date:  2011-07-21

6.  Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus.

Authors:  Tomoyuki Katsuno; Nobuaki Watanabe; Etsuko Nagai; Kazumi Okazaki; Ariko Yokoyama; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  J Diabetes Investig       Date:  2011-06-05       Impact factor: 4.232

7.  Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis.

Authors:  Shinji Kume; Takashi Uzu; Chieko Takagi; Morihiro Kondo; Tomoko Okabe; Shin-Ichi Araki; Keiji Isshiki; Naoko Takeda; Keiko Kondo; Masakazu Haneda; Daisuke Koya; Yoshihiko Nishio; Atsunori Kashiwagi; Hiroshi Maegawa
Journal:  J Diabetes Investig       Date:  2012-06-06       Impact factor: 4.232

8.  Antidiabetic activity of Acacia tortilis (Forsk.) Hayne ssp. raddiana polysaccharide on streptozotocin-nicotinamide induced diabetic rats.

Authors:  Pradeep Kumar Bhateja; Randhir Singh
Journal:  Biomed Res Int       Date:  2014-07-09       Impact factor: 3.411

Review 9.  A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2009-07-20       Impact factor: 9.951

Review 10.  Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus.

Authors:  Hiroyuki Konya; Tomoyuki Katsuno; Taku Tsunoda; Yuzo Yano; Mai Kamitani; Masayuki Miuchi; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  Diabetes Metab Syndr Obes       Date:  2013-09-02       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.